AR and prostate carcinoma: As all AR antagonists were initially developed for prostate cancer, there remains an unmet medical need for additional therapeutic modalities for brain tumors, such as glioblastoma, and a demand for improved formulations of AR antagonists specifically tailored for brain tumors to enhance bioavailability.